After months of rumors, Google introduced its personal smartwatch, referred to as the Pixel Watch, can be coming this fall.
Though the tech big has supported smartwatches via its wearable working system and completed its acquisition of Fitbit final yr, that is Google’s first branded smartwatch. The Pixel Watch may have a round, domed design made with recycled chrome steel and customizable bands.
Despite the fact that the watch additionally has loads of options not involved with well being monitoring, Rick Osterloh, Google’s senior vice chairman of units and companies, teased the Pixel Watch’s “deep integration” with Fitbit that can embody coronary heart charge and sleep monitoring in addition to exercise metrics customers can measure towards their objectives.
In the meantime, Google is getting into a crowded marketplace for health-tracking wearables, with opponents like Apple, Amazon, Samsung, Withings and Garmin. Fitbit just lately landed FDA clearance for its long-awaited photoplethysmography atrial fibrillation (AFib) detection algorithm.
Wysa has acquired FDA Breakthrough Device Designation for its AI-enabled psychological well being chatbot serving to adults with power musculoskeletal ache, despair and anxiousness.
The chatbot affords cognitive behavioral remedy that would reduce despair and anxiousness signs and assist customers handle ache to enhance bodily operate.
The Breakthrough Units program permits corporations to work with the FDA earlier than advertising and marketing approval. It goals to hurry the event, evaluation and overview course of for medical units and mixture merchandise that would present higher therapy for folks with debilitating or life-threatening sicknesses or situations.
“We’re thrilled to attain this significant designation from the FDA and look ahead to working intently with the company to proceed improvement of AI-based cognitive behavioral remedy,” Wysa cofounder and CEO Jo Aggarwal mentioned in an announcement.
“Our mission is to assist these in want of help with an all the time obtainable platform, and through these difficult occasions it’s extra essential than ever to supply psychological well being choices.”
Wysa raised $5.5 million in Series A funding in Could 2021.
Pear Therapeutics is increasing a program to supply its prescription digital therapeutics via partnerships with telehealth suppliers.
The corporate’s latest companion, QuickMD, will be capable of present eligible sufferers with Pear’s opioid use dysfunction product, reSET-O.
In April, the corporate announced the program with its first telehealth providing, addition medicine-focused PursueCare.
“Pear is happy to work with telehealth suppliers in offering modern, FDA-authorized remedies that allow round the clock entry to help eligible sufferers of their restoration journey throughout these tough occasions,” Chief Industrial Officer Julia Strandberg mentioned in an announcement. “After so many unsure months, you will need to meet folks the place they’re and the place they really feel snug, offering them with entry to the care they want.”